Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 2
Submit an article Journal homepage
1,758
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Gail J. Roboza Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY, USAView further author information
,
Karen Yeeb Princess Margaret Cancer Center, Toronto, ON, CanadaView further author information
,
Amit Vermac Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USAView further author information
,
Gautam Borthakurd MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-7679-6453View further author information
ORCID Icon,
Adolfo de la Fuente Burguerae MD Anderson Cancer Center, Madrid, SpainView further author information
,
Guillermo Sanzf Department of Hematology, Hospital Universitario y Politecnico La Fe, Valencia, SpainView further author information
,
Helai P. Mohammadg GSK, Collegeville, PA, USAView further author information
,
Ryan G. Krugerg GSK, Collegeville, PA, USAView further author information
,
Natalie O. Karpinichg GSK, Collegeville, PA, USAView further author information
,
Geraldine Ferron-Bradyg GSK, Collegeville, PA, USAView further author information
,
Andre Acustag GSK, Collegeville, PA, USAView further author information
,
Heather Del Buonog GSK, Collegeville, PA, USAView further author information
,
Therese Collingwoodg GSK, Collegeville, PA, USAView further author information
,
Marc Ballasg GSK, Collegeville, PA, USAView further author information
,
Arindam Dharg GSK, Collegeville, PA, USAView further author information
&
Andrew H. Weih Alfred Hospital and Monash University, Melbourne, VIC, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7514-3298View further author information
ORCID Icon show all
Pages 463-467 | Received 21 Oct 2021, Accepted 22 Nov 2021, Published online: 19 Dec 2021

References

  • Duong VH, Lin K, Reljic T, et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk. 2013;13(6):711–715.
  • Heinicke T, Krahl R, Kahl C, et al. Prognostic factors for overall survival in relapsed acute myeloid leukemia. Blood. 2014;124(21):3666–3666.
  • Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61.
  • Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018;8(5):47.
  • Mohammad HP, Smitheman KN, Kamat CD, et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. 2015;28(1):57–69.
  • Kruger RG, Mohammad H, Smitheman K, et al. Inhibition of LSD1 as a therapeutic strategy for the treatment of acute myeloid leukemia. Blood. 2013;122(21):3964–3964.
  • Duy C, Teater M, Garrett-Bakelman FE, et al. Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML. Cancer Discov. 2019;9(7):872–889.
  • Smitheman KN, Severson TM, Rajapurkar SR, et al. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica. 2019;104(6):1156–1167.
  • Celgene. VIDAZA (azacitidine for injection), for subcutaneous or intravenous use prescribing information 2018. [March 2019]. Available from: https://media.celgene.com/content/uploads/vidaza-pi.pdf.
  • Bauer TM, Besse B, Martinez-Marti A, et al. Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC. J Thorac Oncol. 2019;14(10):1828–1838.
  • Webert K, Cook RJ, Sigouin CS, et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica. 2006;91(11):1530–1537.
  • Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600–613.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.